ライフサイエンスコーパス: Machado-Joseph disease

1 epresents a promising therapeutic target for Machado-Joseph disease.

2 signalling is beneficial in animal models of Machado-Joseph disease.

3 as a neuroprotective therapeutic approach in Machado-Joseph disease.

4 , which causes the neurodegenerative disease Machado-Joseph disease.

5 3, a deubiquitinating enzyme associated with Machado-Joseph disease.

6 uence repeat (SSR) variation associated with Machado-Joseph disease.

7 I, dentatorubral-pallidoluysian atrophy, and Machado-Joseph disease.

8 whether ibuprofen treatment would alleviate Machado-Joseph disease.

9 Mutant ataxin-3, the genetic cause of Machado-Joseph Disease, also contains an expanded CAG re

10 increased longevity in a Drosophila model of Machado-Joseph disease and effectively reduced aggregate

11 a potentially promising therapeutic drug for Machado-Joseph disease and possibly other neurological p

12 nerative polyglutamine disease known both as Machado-Joseph disease and spinocerebellar ataxia type 3

13 cerebellar ataxia type-3 (SCA3), also called Machado-Joseph disease, and is cleaved in mammalian cell

14 ion and induces neuroprotection, alleviating Machado-Joseph disease-associated neuropathology and mot

15 nts, which correlated with preservation from Machado-Joseph disease-associated neuropathology, namely

16 spinocerebellar ataxia type 3, also known as Machado-Joseph disease, causes dendritic and synapse los

17 Patients with Machado-Joseph disease exhibit significant motor impairm

18 -expanded neurotoxic protein (MJDtr78Q; MJD, Machado-Joseph disease) in the major timeless (tim)-expr

19 Machado-Joseph disease is a neurodegenerative disease wi

20 Machado-Joseph disease is caused by an expansion of a tr

21 ter among Jews of North African descent, and Machado-Joseph disease is particularly frequent in Yemen

22 Spinocerebellar ataxia type 3/Machado-Joseph disease is the most common autosomal domi

23 rebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is reported to be the most commo

24 ctive treatment of symptomatic patients with Machado-Joseph disease may require cell replacement, whi

25 transplantation into the cerebellum of adult Machado-Joseph disease mice, cerebellar neural stem cell

26 Huntington's disease (HD) and Machado Joseph Disease (MJD) are severe neurological dis

27 dentatorubral pallidoluysian atrophy (DRPLA) Machado-Joseph disease (MJD or SCA3) and SCA2.

28 These include Machado-Joseph disease (MJD) and Huntington's disease (H

29 found to be dysregulated in blood samples of Machado-Joseph disease (MJD) carriers.

30 Strikingly, we find the Machado-Joseph disease (MJD) class to be unappreciated n

31 Machado-Joseph disease (MJD) is a late-onset, progressiv

32 Machado-Joseph disease (MJD) is a neurodegenerative diso

33 Machado-Joseph disease (MJD) is a neurodegenerative diso

34 Machado-Joseph disease (MJD) is an autosomal dominant ne

35 Machado-Joseph disease (MJD) is an inherited neurodegene

36 Machado-Joseph disease (MJD) is one of at least six neur

37 Machado-Joseph disease (MJD) is the most common dominant

38 The neurodegenerative disease Machado-Joseph disease (MJD), also known as spinocerebel

39 e frequency of SCA2 compared with SCA1, SCA3/Machado-Joseph disease (MJD), and dentatorubropallidoluy

40 RPLA), spinocerebellar ataxia type 1 (SCA1), Machado-Joseph disease (MJD), and Friedreich ataxia.

41 ouped as repeat expansion SCAs, such as SCA3/Machado-Joseph disease (MJD), and rare SCAs that are cau

42 rebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an autosomal-dominant n

43 rformed in patients of Japanese descent with Machado-Joseph disease (MJD), it was reported that disea

44 (ATXN3), a deubiquitylase (DUB) involved in Machado-Joseph Disease (MJD), remains elusive.

45 nd modifier of the molecular pathogenesis of Machado-Joseph disease (MJD), the most common autosomal

46 ed protein in the neurodegenerative disorder Machado-Joseph disease (MJD).

47 ich attaches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).

48 Machado-Joseph disease (MJD; MIM 109150) is a late-onset

49 al data of 292 spinocerebellar ataxia type 3/Machado-Joseph disease mutation carriers.

50 T3) results in spinocerebellar ataxia type 3/Machado-Joseph disease, one of the nine polyglutamine ne

51 Machado-Joseph disease or spinocerebellar ataxia 3 (SCA3

52 Machado-Joseph disease or spinocerebellar ataxia type 3

53 Additionally, neural cultures of Machado-Joseph disease patients' induced pluripotent ste

54 Spinocerebellar ataxia type 3 (SCA3)/Machado Joseph disease results from expansion of the pol

55 Spinocerebellar ataxia type-3 or Machado-Joseph disease (SCA3/MJD) is a member of the CAG

56 n described in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD), an autosomal dominant

57 Spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), is one of at least ei

58 ase protein in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD), or an unrelated green

59 In spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD), the expanded cytosine

60 spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), we show that the dise

61 Machado-Joseph disease (spinocerebellar ataxia type 3) (

62 dominant ataxias was high, particularly for Machado-Joseph disease (spinocerebellar ataxia type 3).

63 e siRNA that exclusively silenced the mutant Machado-Joseph disease/spinocerebellar ataxia type 3 all

64 aging model of spinocerebellar ataxia type 3/Machado-Joseph disease that includes a biomarker stage c

65 replacement and neuroprotective approach for Machado-Joseph disease therapy.

66 ural stem cells into the cerebellum of adult Machado-Joseph disease transgenic mice and assessed the